Share Price and Basic Stock Data
Last Updated: December 16, 2025, 8:02 am
| PEG Ratio | -3.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lasa Supergenerics Ltd operates in the specialty chemicals sector, with a market capitalization of ₹47.8 Cr. The company has seen fluctuating sales over the past few quarters. In June 2023, reported sales were ₹31 lakh, which dipped to ₹24 lakh by September 2023. However, a slight recovery was noted in subsequent quarters, with sales rebounding to ₹39 lakh in September 2024 before settling at ₹33 lakh by December 2024. This volatility raises questions about the company’s demand stability and market positioning. Notably, the overall trend in annual sales has seen a decline from ₹137 Cr in FY 2022 to ₹130 Cr in FY 2023, and further to ₹104 Cr in FY 2024, suggesting underlying challenges that need addressing. The company’s ability to navigate this downturn will be crucial for future growth.
Profitability and Efficiency Metrics
Profitability remains a significant concern for Lasa Supergenerics, as indicated by its negative net profit margins, which stood at -10.35% for FY 2025. The operating profit margin (OPM) reflects a similar struggle, fluctuating between -2% and 13% in recent quarters, indicating that the company has not been able to maintain a consistent operational efficiency. The trailing twelve months (TTM) figures show a net loss of ₹33 lakh, down from a profit of ₹23 lakh in FY 2021, illustrating a downward trajectory. Moreover, the return on equity (ROE) is a mere 1.01%, suggesting that shareholder returns are not being maximized effectively. The interest coverage ratio of 4.19x offers some respite, indicating that the company can comfortably cover its interest obligations, but this does not mitigate the overall profitability concerns.
Balance Sheet Strength and Financial Ratios
On the balance sheet front, Lasa Supergenerics appears to maintain a manageable level of debt, with total borrowings recorded at ₹7 Cr against reserves of ₹6 Cr. This translates to a debt-to-equity ratio of approximately 0.03, which is relatively low, suggesting that the company is not overly leveraged. The current ratio stands at 1.90, indicating that the company has sufficient short-term assets to cover its short-term liabilities, which is a positive sign for liquidity. However, the book value per share has declined significantly from ₹39.07 in FY 2021 to ₹16.71 in FY 2025, highlighting a deterioration in the company’s net worth. Additionally, the cash conversion cycle of 53 days suggests that it may take longer for the company to convert its investments in inventory and receivables back into cash, which could pressure liquidity further.
Shareholding Pattern and Investor Confidence
Investor sentiment reflects a cautious outlook, as Lasa Supergenerics shows a stable promoter holding of 53.65%, with no foreign institutional investments (FIIs) reported, indicating a lack of confidence from external investors. The public holding stands at 46.35%, and the number of shareholders has slightly increased to 28,656, suggesting some level of interest in the stock despite its challenges. However, the absence of institutional investment may raise red flags for potential investors, as institutional backing is often viewed as a vote of confidence in a company’s future prospects. The stability in the promoter holding, however, may indicate a commitment to the company’s long-term vision, which could be a reassuring factor for retail investors.
Outlook, Risks, and Final Insight
Looking ahead, Lasa Supergenerics faces a challenging environment. The declining sales and profitability metrics suggest that the company may struggle to regain its footing without a significant strategic overhaul. Risks include the potential for further declines in revenue, operational inefficiencies, and the lack of institutional support, which could weigh on investor sentiment and stock performance. However, the low leverage and reasonable liquidity position offer some solace. Investors should remain vigilant about the company’s ability to implement effective measures to reverse the current trends. As always, assessing the balance between risks and the potential for recovery will be key in making informed investment decisions regarding Lasa Supergenerics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 393 Cr. | 42.8 | 83.5/41.2 | 24.4 | 20.5 | 0.94 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 29.5 Cr. | 60.0 | 99.5/56.0 | 14.1 | 89.6 | 1.67 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 47.1 Cr. | 693 | 959/600 | 21.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,408 Cr. | 75.2 | 111/74.2 | 22.6 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 645 Cr. | 259 | 453/241 | 23.2 | 93.8 | 0.97 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,943.84 Cr | 732.54 | 65.62 | 183.02 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 34 | 32 | 35 | 31 | 24 | 27 | 23 | 31 | 39 | 33 | 39 | 20 |
| Expenses | 37 | 34 | 34 | 31 | 27 | 23 | 26 | 27 | 29 | 39 | 33 | 36 | 21 |
| Operating Profit | -8 | -0 | -2 | 4 | 4 | 1 | 1 | -4 | 2 | 1 | 0 | 3 | -0 |
| OPM % | -28% | -1% | -8% | 12% | 13% | 4% | 4% | -17% | 6% | 2% | 1% | 9% | -2% |
| Other Income | 0 | -2 | 1 | -19 | 0 | 0 | 0 | -9 | 0 | 2 | 9 | -22 | -20 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 2 |
| Profit before tax | -11 | -7 | -5 | -19 | 1 | -2 | -2 | -16 | -2 | -1 | 6 | -22 | -23 |
| Tax % | 8% | -2% | -4% | -22% | 581% | -99% | -30% | -4% | 47% | 147% | 7% | -35% | -6% |
| Net Profit | -12 | -7 | -5 | -15 | -5 | -0 | -1 | -15 | -3 | -3 | 5 | -14 | -21 |
| EPS in Rs | -2.97 | -1.63 | -1.21 | -2.99 | -0.99 | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 |
Last Updated: August 20, 2025, 7:50 am
Below is a detailed analysis of the quarterly data for Lasa Supergenerics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 19.00 Cr..
- For Expenses, as of Jun 2025, the value is 21.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 15.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Jun 2025, the value is -2.00%. The value appears to be declining and may need further review. It has decreased from 9.00% (Mar 2025) to -2.00%, marking a decrease of 11.00%.
- For Other Income, as of Jun 2025, the value is -20.00 Cr.. The value appears strong and on an upward trend. It has increased from -22.00 Cr. (Mar 2025) to -20.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -23.00 Cr.. The value appears to be declining and may need further review. It has decreased from -22.00 Cr. (Mar 2025) to -23.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is -6.00%. The value appears to be increasing, which may not be favorable. It has increased from -35.00% (Mar 2025) to -6.00%, marking an increase of 29.00%.
- For Net Profit, as of Jun 2025, the value is -21.00 Cr.. The value appears to be declining and may need further review. It has decreased from -14.00 Cr. (Mar 2025) to -21.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -4.22. The value appears to be declining and may need further review. It has decreased from -2.85 (Mar 2025) to -4.22, marking a decrease of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:03 am
| Metric | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 95 |
| Expenses | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 96 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -1 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | -1% | |
| Other Income | 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -33 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 1 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 10 |
| Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -44 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| Net Profit | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -36 |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -7.22 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -200.00% | 133.33% | 475.00% | -121.74% | -680.00% | 43.59% | 31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -700.00% | 333.33% | 341.67% | -596.74% | -558.26% | 723.59% | -11.77% |
Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | 1% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -28% |
| TTM: | 133% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -38% |
| 1 Year: | -73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 9:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:33 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 6 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 7 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 8 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 58 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 13 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
Below is a detailed analysis of the balance sheet data for Lasa Supergenerics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 50.00 Cr..
- For Reserves, as of Sep 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 34.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 2.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing). It has decreased from 16.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 72.00 Cr.. The value appears to be improving (decreasing). It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 20.00 Cr..
- For Total Assets, as of Sep 2025, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
However, the Borrowings (7.00 Cr.) are higher than the Reserves (6.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -70.00 | -66.00 | -74.00 | -18.00 | 28.00 | -4.00 | -28.00 | -20.00 | 4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Diluted EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Cash EPS (Rs.) | -0.49 | -2.21 | -5.03 | 2.12 | 9.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.25 | 0.25 |
| Revenue From Operations / Share (Rs.) | 28.43 | 20.82 | 25.86 | 33.71 | 49.76 |
| PBDIT / Share (Rs.) | 2.25 | 0.45 | -0.95 | 3.86 | 11.62 |
| PBIT / Share (Rs.) | -0.20 | -1.68 | -3.63 | 0.41 | 7.73 |
| PBT / Share (Rs.) | -3.87 | -3.81 | -8.44 | -1.53 | 7.25 |
| Net Profit / Share (Rs.) | -2.94 | -4.34 | -7.71 | -1.32 | 5.60 |
| PBDIT Margin (%) | 7.91 | 2.17 | -3.69 | 11.44 | 23.36 |
| PBIT Margin (%) | -0.71 | -8.05 | -14.05 | 1.23 | 15.54 |
| PBT Margin (%) | -13.60 | -18.31 | -32.62 | -4.52 | 14.57 |
| Net Profit Margin (%) | -10.35 | -20.82 | -29.80 | -3.91 | 11.25 |
| Return on Networth / Equity (%) | -17.62 | -22.47 | -32.65 | -3.61 | 14.33 |
| Return on Capital Employeed (%) | -1.21 | -8.24 | -15.03 | 1.08 | 18.79 |
| Return On Assets (%) | -14.53 | -14.40 | -23.57 | -2.69 | 10.95 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 1.13 | 0.66 | 0.71 | 0.67 | 0.92 |
| Current Ratio (X) | 1.90 | 0.77 | 0.91 | 1.65 | 1.59 |
| Quick Ratio (X) | 0.46 | 0.38 | 0.59 | 1.39 | 1.16 |
| Inventory Turnover Ratio (X) | 4.97 | 4.81 | 8.67 | 6.13 | 4.69 |
| Interest Coverage Ratio (X) | 4.19 | 1.17 | -1.15 | 389.33 | 24.08 |
| Interest Coverage Ratio (Post Tax) (X) | 1.34 | -5.71 | -3.50 | 62.86 | 12.60 |
| Enterprise Value (Cr.) | 86.20 | 108.58 | 90.15 | 152.41 | 239.23 |
| EV / Net Operating Revenue (X) | 0.60 | 1.04 | 0.69 | 1.11 | 1.18 |
| EV / EBITDA (X) | 7.64 | 47.93 | -18.82 | 9.71 | 5.06 |
| MarketCap / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| Price / BV (X) | 1.01 | 1.14 | 0.78 | 1.14 | 1.53 |
| Price / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| EarningsYield | -0.17 | -0.19 | -0.41 | -0.03 | 0.09 |
After reviewing the key financial ratios for Lasa Supergenerics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.49. This value is below the healthy minimum of 3. It has increased from -2.21 (Mar 24) to -0.49, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.43. It has increased from 20.82 (Mar 24) to 28.43, marking an increase of 7.61.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 2.25, marking an increase of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.20. This value is below the healthy minimum of 0. It has increased from -1.68 (Mar 24) to -0.20, marking an increase of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.87. This value is below the healthy minimum of 0. It has decreased from -3.81 (Mar 24) to -3.87, marking a decrease of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 2. It has increased from -4.34 (Mar 24) to -2.94, marking an increase of 1.40.
- For PBDIT Margin (%), as of Mar 25, the value is 7.91. This value is below the healthy minimum of 10. It has increased from 2.17 (Mar 24) to 7.91, marking an increase of 5.74.
- For PBIT Margin (%), as of Mar 25, the value is -0.71. This value is below the healthy minimum of 10. It has increased from -8.05 (Mar 24) to -0.71, marking an increase of 7.34.
- For PBT Margin (%), as of Mar 25, the value is -13.60. This value is below the healthy minimum of 10. It has increased from -18.31 (Mar 24) to -13.60, marking an increase of 4.71.
- For Net Profit Margin (%), as of Mar 25, the value is -10.35. This value is below the healthy minimum of 5. It has increased from -20.82 (Mar 24) to -10.35, marking an increase of 10.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is -17.62. This value is below the healthy minimum of 15. It has increased from -22.47 (Mar 24) to -17.62, marking an increase of 4.85.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.21. This value is below the healthy minimum of 10. It has increased from -8.24 (Mar 24) to -1.21, marking an increase of 7.03.
- For Return On Assets (%), as of Mar 25, the value is -14.53. This value is below the healthy minimum of 5. It has decreased from -14.40 (Mar 24) to -14.53, marking a decrease of 0.13.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.13. It has increased from 0.66 (Mar 24) to 1.13, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has increased from 0.77 (Mar 24) to 1.90, marking an increase of 1.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 24) to 0.46, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.97. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 4.97, marking an increase of 0.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.19. This value is within the healthy range. It has increased from 1.17 (Mar 24) to 4.19, marking an increase of 3.02.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 3. It has increased from -5.71 (Mar 24) to 1.34, marking an increase of 7.05.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.20. It has decreased from 108.58 (Mar 24) to 86.20, marking a decrease of 22.38.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.60, marking a decrease of 0.44.
- For EV / EBITDA (X), as of Mar 25, the value is 7.64. This value is within the healthy range. It has decreased from 47.93 (Mar 24) to 7.64, marking a decrease of 40.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For Price / BV (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.14 (Mar 24) to 1.01, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For EarningsYield, as of Mar 25, the value is -0.17. This value is below the healthy minimum of 5. It has increased from -0.19 (Mar 24) to -0.17, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lasa Supergenerics Ltd:
- Net Profit Margin: -10.35%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.21% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -17.62% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.34
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 97.4 (Industry average Stock P/E: 65.62)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.35%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722 | investor@lasalabs.com http://www.lasalabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Omkar Pravin Herlekar | Chairman & Managing Director |
| Mr. Prathamesh Chalke | Whole Time Director |
| Mr. Ketan Bhau Songal | Independent Director |
| Mr. Pravin Gadalya Lachake | Independent Director |
| Mr. Yogesh Hari Ughada | Independent Director |
| Mrs. Rekha Hemant Wakh | Independent Director |
FAQ
What is the intrinsic value of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd's intrinsic value (as of 16 December 2025) is 8.99 which is 3.64% lower the current market price of 9.33, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 46.7 Cr. market cap, FY2025-2026 high/low of 31.4/8.16, reserves of ₹6 Cr, and liabilities of 72 Cr.
What is the Market Cap of Lasa Supergenerics Ltd?
The Market Cap of Lasa Supergenerics Ltd is 46.7 Cr..
What is the current Stock Price of Lasa Supergenerics Ltd as on 16 December 2025?
The current stock price of Lasa Supergenerics Ltd as on 16 December 2025 is 9.33.
What is the High / Low of Lasa Supergenerics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lasa Supergenerics Ltd stocks is 31.4/8.16.
What is the Stock P/E of Lasa Supergenerics Ltd?
The Stock P/E of Lasa Supergenerics Ltd is 97.4.
What is the Book Value of Lasa Supergenerics Ltd?
The Book Value of Lasa Supergenerics Ltd is 11.2.
What is the Dividend Yield of Lasa Supergenerics Ltd?
The Dividend Yield of Lasa Supergenerics Ltd is 0.00 %.
What is the ROCE of Lasa Supergenerics Ltd?
The ROCE of Lasa Supergenerics Ltd is 1.00 %.
What is the ROE of Lasa Supergenerics Ltd?
The ROE of Lasa Supergenerics Ltd is 1.01 %.
What is the Face Value of Lasa Supergenerics Ltd?
The Face Value of Lasa Supergenerics Ltd is 10.0.